Last reviewed · How we verify

Acute Ischemic Stroke with Malignant Cerebral Edema in the Posterior Circulation — Treatment Landscape & Competitive Intelligence

Acute Ischemic Stroke with Malignant Cerebral Edema in the Posterior Circulation (disease) competitive landscape: 1 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

1 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Acute Ischemic Stroke with Malignant Cerebral Edema in the Posterior Circulation, deduplicated by molecule. See the full disease page for line-of-therapy detail.

DrugGenericSponsorClassTargetLine of therapyFirst approval
Best Available Treatment best-available-treatment Pfizer Not specified Not specified

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

  1. Pfizer · 1 drug in Acute Ischemic Stroke with Malignant Cerebral Edema in the Posterior Circulation

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Acute Ischemic Stroke with Malignant Cerebral Edema in the Posterior Circulation:

Cite this brief

Drug Landscape (2026). Acute Ischemic Stroke with Malignant Cerebral Edema in the Posterior Circulation — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/acute-ischemic-stroke-with-malignant-cerebral-edema-in-the-posterior-circulation. Accessed 2026-06-10.

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing